Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression

A novel human cell line was established from a primary botryoid rhabdomyosarcoma. Reverse transcription polymerase chain reaction investigations of this cell line, called RUCH-2, demonstrated expression of the regulatory factors PAX3, Myf3 and Myf5. After 3.5 months in culture, cells underwent a crisis after which Myf3 and Myf5 could no longer be detected, whereas PAX3 expression remained constant over the entire period. Karyotype analysis revealed breakpoints in regions similar to previously described alterations in primary rhabdomyosarcoma tumour samples. Interestingly, cells progressed to a metastatic phenotype, as observed by enhanced invasiveness in vitro and tumour growth in nude mice in vivo. On the molecular level, microarray analysis before and after progression identified extensive changes in the composition of the extracellular matrix. As expected, down-regulation of tissue inhibitors of metalloproteinases and up-regulation of matrix metalloproteinases were observed. Extensive down-regulation of several death receptors of the tumour necrosis factor family suggests that these cells might have an altered response to appropriate apoptotic stimuli. The RUCH-2 cell line represents a cellular model to study multistep tumorigenesis in human rhabdomyosarcoma, allowing molecular comparison of tumorigenic versus metastatic cancer cells. © 2000 Cancer Research Campaign

[1]  International System for Human Cytogenetic Nomenclature , 2020, Definitions.

[2]  S. Lyons,et al.  Apoptosis and carcinogenesis. , 1999, British medical bulletin.

[3]  B. Kallakury,et al.  Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma , 1998, Cancer.

[4]  F. Barr,et al.  Structural analysis of PAX3 genomic rearrangements in alveolar rhabdomyosarcoma. , 1998, Cancer genetics and cytogenetics.

[5]  F. Mertens,et al.  Chromosomal aberrations in a consecutive series of childhood rhabdomyosarcoma. , 1998, Medical and pediatric oncology.

[6]  D. Beier,et al.  The Matrix Metalloproteinase-14 (MMP-14) Gene Is Structurally Distinct from Other MMP Genes and Is Co-expressed with the TIMP-2 Gene during Mouse Embryogenesis* , 1997, The Journal of Biological Chemistry.

[7]  C. Wolf‐Peeters,et al.  Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. , 1997, The American journal of pathology.

[8]  D. Betts,et al.  Routine karyotyping in Wilms tumor. , 1997, Cancer genetics and cytogenetics.

[9]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[10]  Wyllie Ah.  Apoptosis and carcinogenesis. , 1997 .

[11]  John Calvin Reed,et al.  Anti-cell death activity promotes pulmonary metastasis of melanoma cells , 1997, Oncogene.

[12]  G. Glinsky,et al.  Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. , 1997, Cancer letters.

[13]  K. Pritchard-Jones,et al.  Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. , 1996, Cancer research.

[14]  M. Silen.  Classification of rhabdomyosarcomas and related sarcomas: W.A. Newton, Jr, E.A. Gehan, B.L. Webber, et al. Cancer 76:1073–1085, (September), 1995 , 1996 .

[15]  S. F. Konieczny,et al.  Transcription factor families: muscling in on the myogenic program , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  H. B. Marsden,et al.  Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification‐an intergroup rhabdomyosarcoma study , 1995, Cancer.

[17]  B. Schäfer,et al.  Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes. , 1994, Nucleic acids research.

[18]  A. Pappo,et al.  Rhabdomyosarcoma and other soft tissue sarcomas of childhood. , 1994, Current opinion in oncology.

[19]  J. Biegel,et al.  Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. , 1994, Cancer research.

[20]  J. Downing,et al.  Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. , 1993, Cancer research.

[21]  B. Emanuel,et al.  Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[22]  J. Biegel,et al.  Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[23]  T. Triche,et al.  Cytogenetic studies in subgroups of rhabdomyosarcoma , 1992, Genes, chromosomes & cancer.

[24]  L. Diller.  Rhabdomyosarcoma and other soft tissue sarcomas of childhood , 1992, Current opinion in oncology.

[25]  T. Braun,et al.  Expression of members of the myf gene family in human rhabdomyosarcomas. , 1991, British Journal of Cancer.

[26]  P. Tonin,et al.  Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. , 1991, Cancer research.

[27]  B. Lampkin,et al.  Chromosomal analysis of sixteen human rhabdomyosarcomas. , 1988, Cancer research.

[28]  W. Cavenee,et al.  Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping , 1987, Nature.

[29]  P. Lollini,et al.  RMZ: a new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin. , 1986, British Journal of Cancer.

[30]  M. Gardner,et al.  Cultivation in vitro of cells derived from a human rhabdomyosarcoma , 1969, Cancer.

[31]  E. Prochownik,et al.  Rhabdomyosarcomas do not contain mutations in the DNA binding domains of myogenic transcription factors. , 1994, The Journal of clinical investigation.